title: Phase II trial of sequential methotrexate and 5-fluorouracil with leucovorin in children with sarcomas.
authors.affiliation: Pediatric Branch, National Cancer Institute, Bethesda, MD.
authors.forename: F M
authors.initials: FM
authors.lastname: Balis
authors.forename: A
authors.initials: A
authors.lastname: Gillespie
authors.forename: J
authors.initials: J
authors.lastname: Belasco
authors.forename: G H
authors.initials: GH
authors.lastname: Reaman
authors.forename: L J
authors.initials: LJ
authors.lastname: Ettinger
authors.forename: R F
authors.initials: RF
authors.lastname: Murphy
authors.forename: K
authors.initials: K
authors.lastname: Doherty
authors.forename: S
authors.initials: S
authors.lastname: Jeffries
authors.forename: M E
authors.initials: ME
authors.lastname: Horowitz
authors.forename: D G
authors.initials: DG
authors.lastname: Poplack
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002851:Chromatography, High Pressure Liquid; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004357:Drug Synergism; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D006801:Humans; D007262:Infusions, Intravenous; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D012208:Rhabdomyosarcoma / Q000188:drug therapy*; D012512:Sarcoma, Ewing / Q000188:drug therapy*
chemical_list: D002955:Leucovorin; D005472:Fluorouracil; D008727:Methotrexate